The Reaction Project

HONcode

This site complies with the HONcode standard for trust worthy health information:
verify here.

Affiliations

REACTION is affilliated with these programs and organisations:

REACTION is delivering better and more efficient healthcare services in Europe, thus supporting the Commissions activities in ICT for Health: eHealth.

The REACTION platform allows for the creation of inclusive applications with accessibility for all. The project supports the Commissions campaign: eInclusion - be part of it!

Sign In

Forgotten your password?
Request a new one here.

Facts

The REACTION project is a 4-year project started in 2010. It is partly funded by the European Commission under the 7th Framework Programme in the area of Personal Health Systems under Grant Agreement no. 248590

Impressum

Privacy

Previous Newsletters

Read previous issues of our newsletter here:

April 2014
August 2013
June 2012
August 2011
April 2011
November 2010

Most Read...

Articles

In-hospital saf...	185169
Reaction in the...	111411
Project overview	104809
Medical background	104031
Project methodo...	78567

News

Research award ...	56048
IST-Africa Call...	52014
REACTION at one...	50035
REACTION videos...	48506
REACTION online...	47150

Popular Downloads

REACTION brochure	30121
Design of a mobil...	13007
D9-4 Healthcare e...	11056
D9-2 Regulatory f...	8387
2_Regulatory Fram...	6506

eHealth at Facebook

Join the discussion on EC eHealth at Facebook!

Oh no! Where's the JavaScript?
Your Web browser does not have JavaScript enabled or does not support JavaScript. Please enable JavaScript on your Web browser to properly view this Web site, or upgrade to a Web browser that does support JavaScript.

Downloads: A minimally invasive chip based near infrared sensor for continuous glucose monitoring

Downloads Home > Scientific conference papers > A minimally invasive chip based near infrared sensor for continuous glucose monitoring

A minimally invasive chip based near infrared sensor for continuous glucose monitoring

Abstract: Assessment of glycaemia in diabetes is crucially important for prevention of both, acute and long term complications. Continuous glucose monitoring (CGM) is certainly the most appropriate way for optimizing the glycaemic control, since it prevents or delays the progression of complications associated with hypo- or hyperglycaemic events, reducing morbidity, mortality, and overall costs in health care systems. In this paper we describe the concept and first in vitro results of a minimally invasive, chip-based NIR-Sensor for continuous glucose monitoring. The sensor concept is based on difference infrared absorption spectroscopy, which was evaluated within laboratory measurements of D+-Glucose dissolved in water. The laboratory measurements revealed a linear relationship between glucose concentration and the integrated difference spectroscopy signal with a coefficient of determination of 99.6% in the concentration range of 0- 500 mg/dL. Suitable wavelength bands were identified in which the correlation is preserved and commercial light sources are available for realisation of a spectrometer-less, integrated NIR-sensor. In the designed sensor the component area (non-disposable) is separated from the detection area (disposable, low-cost). The disposable part of the sensor is fluidically connected to a micro-dialyses needle, accessing glucose subcutaneously via the ISF (interstitial fluid) or intravascularly. The non-disposable part contains all the optical elements, like LEDÂ´s and photo-detectors. The in- and out-coupling of the optical signal is achieved across the plane of the chip by using total internal reflection on mirrors integrated into the fluidic chip. The glucose is continuously measured by considering the difference signals of light at the corresponding wavelengths, as a function of time or in defined intervals if the light sources are modulated. The in-vitro measurements show an absolute error of about 5 mg/dL with a relative error of 5% for glucose concentrations larger than 50 mg/dL and about 12 % in the hypoglycemic range (<50 mg /dL).